| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.88B | +23.6% |
| Cost of Revenue | $309.7M | +20.3% |
| Gross Profit | $2.57B | +24.0% |
| R&D Expense | $481.0M | +17.9% |
| SG&A Expense | $709.7M | +48.8% |
| Operating Income | $1.38B | +16.2% |
| Pre-tax Income | $1.54B | +20.8% |
| Income Tax | $343.9M | +18.8% |
| Net Income | $1.20B |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.70B | +40.5% |
| Short-term Investments | $1.57B | -12.1% |
| Accounts Receivable | $279.3M | +0.1% |
| Inventory | $157.9M | +41.2% |
| Current Assets | $3.87B | +9.1% |
| Total Assets | $7.36B | +2.7% |
| Current Liabilities | $738.1M | -8.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.33B | +35.7% |
| Capital Expenditures | $246.5M | +7.0% |
| Investing Cash Flow | $417.2M | +158.0% |
| Financing Cash Flow | -$1.25B | — |
| Free Cash Flow | $1.08B | +44.5% |
| +21.4% |
| EPS (Basic) | $26.44 | +25.7% |
| EPS (Diluted) | $24.64 | +24.4% |
| Total Liabilities |
| $920.0M |
| -22.2% |
| Stockholders' Equity | $6.44B | +7.7% |